| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5194247 | ALMIRALL | Synergistic skin depigmentation composition |
Dec, 2013
(10 years ago) | |
| US6353029 | ALMIRALL | Storage stable tretinoin and 4-hydroxyanisole containing topical composition |
Aug, 2020
(3 years ago) | |
Solage is owned by Almirall.
Solage contains Mequinol; Tretinoin.
Solage has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Solage are:
- US5194247
- US6353029
Solage was authorised for market use on 10 December, 1999.
Solage is available in solution;topical dosage forms.
Solage can be used as treatment of hyperpigmentary disorders.
The generics of Solage are possible to be released after 24 August, 2020.
Drugs and Companies using MEQUINOL; TRETINOIN ingredient
Market Authorisation Date: 10 December, 1999
Treatment: Treatment of hyperpigmentary disorders
Dosage: SOLUTION;TOPICAL
More Information on Dosage
SOLAGE family patents
